Anvisa approves new treatment for aggressive non-Hodgkin lymphoma

Brazil's health regulatory agency, Anvisa, has authorized a new medication for adult patients diagnosed with aggressive non-Hodgkin lymphoma. The approval expands the therapeutic options available for this specific blood cancer, though the specific drug name and clinical efficacy data were not detailed in the initial report.